Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858962 · ClinicalTrials.gov registry record · NA
Buprenorphine/Raltegravir Pharmacokinetic Interaction Study
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00858962 is a NA study that has completed, run by Yale University. The registered enrollment target is 12 participants.
The verdict
NCT00858962, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The main purpose of this protocol is to study the effect of an HIV medication known as Raltegravir on Buprenorphine in people who have been receiving the same dose of Buprenorphine for at least 3 weeks before study entry. This will be determined by giving Raltegravir along with Buprenorphine and by measuring the amount of Raltegravir and Buprenorphine in the blood. The investigators will also learn about the effects of Buprenorphine on Raltegravir and about the safety of taking these two medications together.
Interventions
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00858962
The ClinicalTrials.gov registry entry for NCT00858962 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Raltegravir is the first listed.
NCT00858962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00858962 about?
NCT00858962 is a clinical study titled "Buprenorphine/Raltegravir Pharmacokinetic Interaction Study". The main purpose of this protocol is to study the effect of an HIV medication known as Raltegravir on Buprenorphine in people who have been receiving the same dose of Buprenorphine for at least 3 weeks before study entry. This will be determined by giving Raltegravir along with Buprenorphine and by ...
What is the current status of trial NCT00858962?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2009-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00858962?
The interventions under investigation include: Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00858962?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.